122 related articles for article (PubMed ID: 8036743)
1. Use of synthetic peptides in primates to induce high-titered neutralizing antibodies and MHC class I-restricted cytotoxic T cells against acquired immunodeficiency syndrome retroviruses: an HLA-based vaccine strategy.
Haynes BF; Yasutomi Y; Torres JV; Gardner MB; Langlios AJ; Bolognesi DP; Matthews TJ; Scearce RM; Jones DM; Moody MA
Trans Assoc Am Physicians; 1993; 106():33-41. PubMed ID: 8036743
[No Abstract] [Full Text] [Related]
2. Simian immunodeficiency virus as a model for vaccination against HIV. Induction in rhesus macaques of GAG- or NEF-specific cytotoxic T lymphocytes by lipopeptides.
Bourgault I; Chirat F; Tartar A; Lévy JP; Guillet JG; Venet A
J Immunol; 1994 Mar; 152(5):2530-7. PubMed ID: 8133061
[TBL] [Abstract][Full Text] [Related]
3. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
[TBL] [Abstract][Full Text] [Related]
4. Preliminary results of V3 loop peptide-primary neutralizing domain conjugate phase 1 vaccine trail.
Rubinstein A; Goldstein H; Pettoello-Mantovani M; Cryz SJ
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S149-53. PubMed ID: 7865291
[No Abstract] [Full Text] [Related]
5. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses.
Kumar A; Lifson JD; Silverstein PS; Jia F; Sheffer D; Li Z; Narayan O
Virology; 2000 Aug; 274(1):149-64. PubMed ID: 10936096
[TBL] [Abstract][Full Text] [Related]
6. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
7. Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope.
Letvin NL; Robinson S; Rohne D; Axthelm MK; Fanton JW; Bilska M; Palker TJ; Liao HX; Haynes BF; Montefiori DC
J Virol; 2001 May; 75(9):4165-75. PubMed ID: 11287566
[TBL] [Abstract][Full Text] [Related]
8. Heterologous neutralizing antibody induction in a simian-human immunodeficiency virus primate model: lack of original antigenic sin.
Rasmussen RA; Montefiori DC; Robinson HL; McClure HM; Ruprecht RM
J Infect Dis; 2001 Dec; 184(12):1603-7. PubMed ID: 11740737
[TBL] [Abstract][Full Text] [Related]
9. Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides.
Haynes BF; Torres JV; Langlois AJ; Bolognesi DP; Gardner MB; Palker TJ; Scearce RM; Jones DM; Moody MA; McDanal C
J Immunol; 1993 Aug; 151(3):1646-53. PubMed ID: 8335949
[TBL] [Abstract][Full Text] [Related]
10. Strong immunogenicity of a multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infection.
Okuda K; Kaneko T; Yamakawa T; Tanaka S; Shigematsu T; Yamamoto A; Hamajima K; Nakajima K; Kawamoto S; Phanuphak P
J Mol Recognit; 1993 Sep; 6(3):101-9. PubMed ID: 8060667
[TBL] [Abstract][Full Text] [Related]
11. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a synthetic vaccine construct as antigen for the detection of HIV-induced humoral responses.
Hewer R; Meyer D
Vaccine; 2005 Mar; 23(17-18):2164-7. PubMed ID: 15755588
[TBL] [Abstract][Full Text] [Related]
13. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
[TBL] [Abstract][Full Text] [Related]
14. Neutralization sensitivity of a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2N) isolated from an infected rhesus macaque with neurological disease.
Song B; Cayabyab M; Phan N; Wang L; Axthelm MK; Letvin NL; Sodroski JG
Virology; 2004 Apr; 322(1):168-81. PubMed ID: 15063126
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
[TBL] [Abstract][Full Text] [Related]
16. [Induction of neutralizing antibodies against HIV-1 viruses in HLA-DQ6 mice by peptide vaccines].
Takahashi A
Hokkaido Igaku Zasshi; 1998 Mar; 73(2):147-56. PubMed ID: 9612708
[TBL] [Abstract][Full Text] [Related]
17. Polygene DNA vaccine induces a high level of protective effect against HIV-vaccinia virus challenge in mice.
Shinoda K; Xin KQ; Jounai N; Kojima Y; Tamura Y; Okada E; Kawamoto S; Okuda K; Klinman D; Okuda K
Vaccine; 2004 Sep; 22(27-28):3676-90. PubMed ID: 15315847
[TBL] [Abstract][Full Text] [Related]
18. Genotypic and phenotypic variation of HIV-1: impact on AIDS pathogenesis and vaccination.
Wolfs TF; Nara PL; Goudsmit J
Chem Immunol; 1993; 56():1-33. PubMed ID: 8383980
[No Abstract] [Full Text] [Related]
19. Viral evolution in macaques coinfected with CCR5- and CXCR4-tropic SHIVs in the presence or absence of vaccine-elicited anti-CCR5 SHIV neutralizing antibodies.
Burke B; Derby NR; Kraft Z; Saunders CJ; Dai C; Llewellyn N; Zharkikh I; Vojtech L; Zhu T; Srivastava IK; Barnett SW; Stamatatos L
Virology; 2006 Nov; 355(2):138-51. PubMed ID: 16920175
[TBL] [Abstract][Full Text] [Related]
20. Immunization with recombinant BCG-SIV elicits SIV-specific cytotoxic T lymphocytes in rhesus monkeys.
Yasutomi Y; Koenig S; Haun SS; Stover CK; Jackson RK; Conard P; Conley AJ; Emini EA; Fuerst TR; Letvin NL
J Immunol; 1993 Apr; 150(7):3101-7. PubMed ID: 8454878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]